Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers

Fosmanogepix (FMGX, APX001), a first-in-class, intravenous (i.v.) and oral (p.o.) antifungal prodrug candidate is currently in clinical development for the treatment of invasive fungal infections. Manogepix (MGX, APX001A), the active moiety of FMGX, interferes with cell wall synthesis by targeting f...

Descripción completa

Detalles Bibliográficos
Autores principales: Hodges, Michael R., Ople, Eric, Wedel, Pamela, Shaw, Karen J., Jakate, Abhijeet, Kramer, William G., van Marle, Sjoerd, van Hoogdalem, Ewoud-Jan, Tawadrous, Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112065/
https://www.ncbi.nlm.nih.gov/pubmed/36988461
http://dx.doi.org/10.1128/aac.01623-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112065/
https://www.ncbi.nlm.nih.gov/pubmed/36988461
http://dx.doi.org/10.1128/aac.01623-22

Ejemplares similares